JP2013533264A - 成長ホルモンコンジュゲート - Google Patents

成長ホルモンコンジュゲート Download PDF

Info

Publication number
JP2013533264A
JP2013533264A JP2013520079A JP2013520079A JP2013533264A JP 2013533264 A JP2013533264 A JP 2013533264A JP 2013520079 A JP2013520079 A JP 2013520079A JP 2013520079 A JP2013520079 A JP 2013520079A JP 2013533264 A JP2013533264 A JP 2013533264A
Authority
JP
Japan
Prior art keywords
growth hormone
compound
acid
hgh
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013520079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533264A5 (enExample
Inventor
ヘンリク・スーン・アンデルセン
ケル・マスン
ヘレ・デムート
クリスティーネ・ブルーン・シュト
ライフ・ナアスコウ−ラウリトスン
ピーター・テューイェスン
カルステン・ベーレンス
メッテ・グルドブラント
Original Assignee
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ・ノルディスク・ヘルス・ケア・アーゲー filed Critical ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Publication of JP2013533264A publication Critical patent/JP2013533264A/ja
Publication of JP2013533264A5 publication Critical patent/JP2013533264A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2013520079A 2010-07-22 2011-07-15 成長ホルモンコンジュゲート Withdrawn JP2013533264A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10170439.3 2010-07-22
EP10170439 2010-07-22
US36770410P 2010-07-26 2010-07-26
US61/367,704 2010-07-26
PCT/EP2011/062152 WO2012010516A1 (en) 2010-07-22 2011-07-15 Growth hormone conjugates

Publications (2)

Publication Number Publication Date
JP2013533264A true JP2013533264A (ja) 2013-08-22
JP2013533264A5 JP2013533264A5 (enExample) 2014-08-21

Family

ID=43016576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520079A Withdrawn JP2013533264A (ja) 2010-07-22 2011-07-15 成長ホルモンコンジュゲート

Country Status (5)

Country Link
US (1) US20130143815A1 (enExample)
EP (1) EP2595661A1 (enExample)
JP (1) JP2013533264A (enExample)
CN (1) CN103269720A (enExample)
WO (1) WO2012010516A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501144A (ja) * 2015-12-02 2019-01-17 ハンミ ファーマシューティカル カンパニー リミテッド 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法
WO2022145444A1 (ja) * 2020-12-28 2022-07-07 中外製薬株式会社 アミノ酸の固相合成用樹脂への担持方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509102B (zh) * 2012-06-15 2015-07-22 郭怀祖 野生型人生长激素突变体
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
EP3079722B1 (en) 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Method for thioether conjugation of proteins
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
SI3661562T1 (sl) 2017-08-04 2025-01-31 Amgen Inc. Postopek konjugiranja CYS-MABS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009163A2 (en) * 1999-07-30 2001-02-08 The University Court Of The University Of Glasgow Improvement of peptide transport by conjugation with bile acids
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
JP2005500831A (ja) * 2001-06-14 2005-01-13 ザ スクリプス リサーチ インスティチュート 操作されたジスルフィド結合を有する安定化蛋白質
WO2010015668A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
WO2011089250A2 (en) * 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
DE68929151T2 (de) 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
US5849535A (en) 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US6656922B2 (en) * 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
CA2672267C (en) 2006-07-27 2016-05-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
WO2008027854A2 (en) 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
JP5390404B2 (ja) 2007-02-16 2014-01-15 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための環状部分を有する化合物及び組成物
GB0716328D0 (en) 2007-08-21 2007-10-03 Univ Bath Detection and functionalisation of S-nitrosylated polypeptides
KR20110122100A (ko) * 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
US6608183B1 (en) * 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2001009163A2 (en) * 1999-07-30 2001-02-08 The University Court Of The University Of Glasgow Improvement of peptide transport by conjugation with bile acids
JP2005500831A (ja) * 2001-06-14 2005-01-13 ザ スクリプス リサーチ インスティチュート 操作されたジスルフィド結合を有する安定化蛋白質
WO2010015668A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
WO2011089250A2 (en) * 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501144A (ja) * 2015-12-02 2019-01-17 ハンミ ファーマシューティカル カンパニー リミテッド 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法
WO2022145444A1 (ja) * 2020-12-28 2022-07-07 中外製薬株式会社 アミノ酸の固相合成用樹脂への担持方法

Also Published As

Publication number Publication date
EP2595661A1 (en) 2013-05-29
WO2012010516A1 (en) 2012-01-26
US20130143815A1 (en) 2013-06-06
CN103269720A (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
CN102834109B (zh) 稳定的生长激素化合物
JP5980689B2 (ja) 安定な成長ホルモン化合物
JP6086528B2 (ja) 長期のインビボ有効性を有する成長ホルモン
EP3307768B1 (en) Selective pyy compounds and uses thereof
JP5252458B2 (ja) 新規タンパク質コンジュゲート及びその製造方法
AU2014350197A1 (en) Selective PYY compounds and uses thereof
JP2013533264A (ja) 成長ホルモンコンジュゲート
JP2008543297A (ja) トランスグルタミナーゼを介した成長ホルモンのコンジュゲート
CN102027007A (zh) 长效的y2和/或y4受体激动剂
JP5816097B2 (ja) 安定な成長ホルモン化合物
EP3068795A1 (en) Hpyy(1 -36) having a beta-homoarginine substitution at position 35
JP2008516621A (ja) 成長ホルモン結合体
JP2008545644A (ja) 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151214

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160606